



UNIVERSITY OF TABUK
FACULTY OF APPLIED MEDICAL SCIENCES
 Department of Medical Laboratory Technology

CURRICULUM VITAE



DR. AB .RASHID MIR, PhD

Assistant Professor, Faculty of Applied Medical Sciences
 SUPERVISOR- Division of Cancer Molecular Genetics,
 Prince Fahd Bin Sultan Research chair
 University of Tabuk, Saudi Arabia, Tabuk 71491

EDUCATION QUALIFICATIONS

Degree	University/Board	Year
PhD Medical Biochemistry	University of Delhi Faculty of Medical Sciences, , India	Feb 2007-July 2011
M.Sc Biochemistry	University of Jamia Hamdard New Delhi, India	July 2001-2003
M.Sc Medical Lab technology	Punjab Technical University, Jalandhar- Punjab, India	2011-2012
B.Sc Science	University of Kashmir Islamia College of science and commerce, India	1995-1999

PROFESSIONAL EXPERIENCE

POST	UNIVERSITY	YEAR
Assistant Professor And Supervisor	University of Tabuk Faculty of Applied Medical Science Prince Fahd Bin Sultan Research Chair	13 Oct 2014 to till date
Young Scientist (RA)	Sher-i-Kashmir Institute of Medical Sciences Department of Clinical Biochemistry, J & K -India	Oct 2013 to 10 oct 2014
Young Scientist (RA)	University of Delhi Maulana Azad Medical College, Department of Biochemistry, New Delhi India	July 2012 to Oct 2013
Post Doc Fellow (SRF)	University of Delhi Maulana Azad Medical College, Department of Biochemistry, New Delhi India	June 2011 to June 2012
Senior Research Fellow	All India Institute of Medical Sciences Department of Hematology, New Delhi India	June 2005-june 2011
Junior Research Fellow	All India Institute of Medical Sciences Department of Medical Oncology, New Delhi	Sept 2003-March 2005

RESEARCH TRAINING in United States

- ❖ Done Comprehensive Cancer Research Training Program at Molecular Diagnostics Lab, Department of Leukemia, MD Anderson Cancer hospital, Houston, Texas, United states of America. Oct 13 2010.

AWARDS AND SCHOLARSHIPS

- ❖ **Young Investigator Award** from International Society for Laboratory Hematology, 2009 Las Vegas, USA 12 May 2009.
- ❖ **Young Scientist Award** from Human Genome Organization international limited the HCCS 2008 at Singapore on 12 to 14 Nov 2008.
- ❖ **Merit Award Winner** from American Society of Clinical Oncology, 2008 Annual Meeting on Molecular Markers in Cancer October 30 in Hollywood, FL. USA .
- ❖ **Scholar-in-Training Award** from American Association of Cancer Research in an international conference entitled Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine July 20-23, 2008, Hyatt Regency Monterey, California
- ❖ **International Travel Fellowship** from European Society of Hematology in 10th International conference: CML - Biological Basis of Therapy. Portugal, 2013
- ❖ **International Travel Fellowship** from JSMO 2013. Sendai Japan , 2013
- ❖ **Winner of Trainee Award** 2009 by American Society of Investigative Pathology, to attend Experimental Biology meeting in New Orleans, USA .
- ❖ **Travel Grant Award IMPAKT Breast Cancer Conference**, 5-7 May 2011, Brussels, Belgium.
- ❖ **International Travel grant Award** , Department of leukemia, M D Anderson Cancer Hospital ,Houston,Texas ,USA Oct 13 2010.
- ❖ **International Travel Fellowship** from European Society of Hematology in 10th International conference: CML - Biological Basis of Therapy. Boston, USA September
- ❖ **A.D Sobel Award** in an international conference conducted by American Society of Investigative Pathology, Italy 2008.
- ❖ **International Travel grant Award** from Department of Science and Technology, New Delhi to attend Leukemia 2008,Houston ,USA2008,Houston ,TX,USA
- ❖ **Ist and Best poster Presentation Award** in an international conference entitled Molecular insights to treatment paradigms, Mumbai conducted by European School of Oncology, UICC and INCTR 2008.
- ❖ **Ist and Best poster presentation award** in a national conference entitled Molecular Medicine Update in Maulana Azad Medical College, University of Delhi,India .

PROFESSIONAL AFFILIATIONS

- University of Tabuk, Kingdom of Saudi Arabia.
- Maulana Azad Medical College, University of Delhi, India
- Department of Clinical Biochemistry, Sher-i-Kashmir Institute of Medical Sciences, Srinagar
- All India Institute of Medical Sciences, India.
- MDL-Deptt of Leukemia, MD Anderson, Texas-USA

RESEARCH PROJECTS

Project title	Agency	Investigator
JAK-STAT signaling in the pathogenesis of hematological malignancies”	University of Tabuk	Investigator
Genetic abnormalities in the Acute myeloid leukemia patients of Tabuk region.	University of Tabuk	Co-Investigator
Genetic alterations in the pathogenesis of Breast Cancer patients of Tabuk region	University of Tabuk	Investigator
Molecular basis of familial hypercholesterolemia in Saudi Population: Spectrum of gene mutation and genotype -phenotype correlations.	University of Tabuk	Investigator
“Genetic alterations in the pathogenesis of Sickle cell disease (SCD)”	University of Tabuk	Investigator
Incidence of Nicotinic receptor genetic variations among Tabuk populations	University of Tabuk	Investigator

PROFESSIONAL INVOLVEMENTS

- **Vice Chairman**, Research & Publication Committee, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, KSA.
- **President** -Society of cancer research, India.
- **Editor**, International Journal of Genetics and Cancer.

PUBLICATIONS

1. Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A. **Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.** PLoS One. 2016 Apr 19;11(4):e0153902
2. Abu-Duhier F, Mir R. **GSTT1 (rs4025935) null genotype is associated with increased risk of sickle cell disease in the populations of Tabuk-Northwestern region of Saudi Arabia.** Hematology. 2016 Nov 25:1-6.
3. Mir R, Najjar IA, Guru S, Javaid J, Yadav P, Masroor M, Zuberi M, Farooq S, Bhat M, Gupta N, Ray PC, Saxena A. **A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.** Leuk Lymphoma. 2016 Nov 10:1-8
4. Mir R, Bhat MA, Javaid J, Shah N, Kumar P, Sharma E, Jhu C, Basak S, Amle D, Ray PC, Saxena A, Banu S. **Glutathione S-transferase M1 and T1 (rs4025935 and rs71748309) null genotypes are associated with increased susceptibility to coronary artery disease in Indian populations.** Acta Cardiol. 2016;71(6):678-684.
5. Mir R, Masroor M, Javid J, Ahamad I, Farooq S, Yadav P, Zuberi M, Lone M, Ray PC, Saxena A. **Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients.** South Asian J Cancer. 2016 Jan-Mar;5(1):33-6. doi: 10.4103/2278-330X.179701.
6. Javid J, Mir R, Saxena A. **Involvement of CASP3 promoter polymorphism (-1337 C > G) in the development and progression of non-small cell lung cancer.** Tumour Biol. 2016 Jan 15.
7. Yadav P, Masroor M, Tanwer K, Mir R, Javid J, Ahmad I, Zuberi M, Kaza RC, Jain SK, Khurana N, Ray PC, Saxena A. **Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.** Clin Transl Oncol. 2016 Jul;18(7):728-34..
8. Dholariya S, Mir R, Zuberi M, Yadav P, Gandhi G, Khurana N, Saxena A, Ray PC. **Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.** Clin Transl Oncol. 2016 Jan;18(1):73-81.
9. **Glutathione S-transferase M1 & T null genotype are associated with increased susceptibility to Coronary artery disease among Indian populations.** - Ref.: Ms. No. AC-2015-08280R2 year 2016/Feb Acta Cardiologica .
10. Rashid Mir, Fawzia Sharaf, Abu-Duhier FM. **Hemoglobin Subunit Beta Gene Polymorphism rs33949930 T>C and Risk of Sickle Cell Disease—A Case Control Study from Tabuk (Northwestern Part of Saudi Arabia)-** International Journal of Clinical Medicine Pub. Date: January 22, 2016 <http://www.scirp.org/journal/ijcm>.
11. Rashid Mir, Abdullah Y Hamadi, Abu-Duhier FM. Frequency of Null phenotypes of glutathione S-transferase M1 and T1 among the populations of Tabuk (Northwestern part of Saudi Arabia). Open Journal of Genetics January 2016 <http://www.scirp.org/journal/ojgen> (Accepted).
12. Jamsheed Javid · Rashid Mir · Alpana Saxena. **Involvement of CASP3 promoter polymorphism (-1337 C > G) in the development and progression of non-small cell lung cancer .** No preview · Article · Jan 2016 · Tumor Biology
13. **Rashid Mir, Imtiyaz Ahamad, Jamsheed Javid, Shazia Farooq, Prasant Yadav, Alpana saxena, et al.** Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the B3A2 and B2a2 transcripts to Imatinib resistance in north Indian Chronic Myeloid Leukemia patients. Indian J Cancer 2015 Impact Factor 1.13 (accepted).
14. Hasan SK, Sazawal S, Kumar B, Chaubey R, Mishra P, Rashid Mir, Chaudhry VP, Saxena R. **Childhood CML in India: b2a2 transcript is more common than b3a2.** Cancer Genet Cytogenet. 2006 Aug;169(1):76-7.
15. Sazawal S, Kumar B, Hasan SK, Dutta P, Kumar R, Chaubey R, **Rashid Mir, Saxena R.** Haematological & molecular profile of acute myelogenous leukaemia in India. Indian J Med Res. 2009 Mar;129(3)

16. Jamsheed J, **Rashid Mir**, P.K Julka, P.C Ray, Alpana saxena. **Extra cellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of Non Small Cell Lung Cancer patients.** Tumour Biol. 2015. DOI: 10.1007/s13277-015-3062-6. (Impact Factor 3.84).
17. **Rashid Mir**, Imtiyaz Ah, Jamsheed Javid, Mariyam Zuberi, Alpana Saxena et al. **Polymorphism T81C in H-RAS Oncogene is associated with disease progression in Imatinib (TKI) treated chronic myeloid Leukemia Patients.** World J Oncol. 2015; 6(2):321-328.
18. Zuberi M, **Rashid Mir**, Das J, Ahmad I, Jamsheed Javid, Yadav P, Saxena A. et al. **Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.** Clin Transl Oncol. 2015 DOI: 10.1007/s12094-015-1303-1 (Impact Factor: 2.1) *PUBMED*.
19. Zuberi M, **Rashid Mir**, Dholariya S, Imtiyaz N, Prasant Y, Jamsheed Javid, Saxena A et al. **RASSF1 & PTEN promoter hypermethylation influences the outcome in epithelial ovarian Cancer.** Clinical Ovarian and Other Gynecologic Cancer. 2015 DOI: 10.1016/j.cogc.2014.12.002.
20. Imtiyaz A, **Rashid M**, Jamsheed Javid, Shazia F, Prasant Y, Alpana S et al. **Epigenetic Silencing of P16 (INK4a) Gene by Promoter Hypermethylation in Chronic Myelogenous Leukemia.** Clin Lymphoma Myeloma LeukDOI:10.1016/j.clml.2014.06.072 (Impact Factor: 2.02) *PUBMED*.
21. **Rashid Mir**, Imtiyaz Ahamad, Jamsheed Javid, Shazia Farooq, Prasant Yadav, Alpana saxena, et al. **Epigenetic Silencing of DAPK1 Gene is Associated with Faster Disease Progression in Indian Populations with Chronic Myeloid Leukemia.** J Cancer Sci Ther. 2013; 5(4):144-149. (Impact Factor: 3.09).
22. Imtiyaz Ah, **Rashid Mir**, Sameer G, Jamsheed Javid, Mariyam Z, Alpana saxena, et al. **Inactivation of P16 (INK4a) Gene by Promoter Hypermethylation is Associated with Disease Progression in Chronic Myelogenous Leukaemia.** J Carcinogenesis & Mutagenesis. 2013; 4(2):1-6. (Impact Factor: 1.46).
23. **Rashid Mir**, Mariyam Zuberi, Imtiyaz Ahmad, Jamsheed Javid, Prasant Yadav, Alpana saxena, et al. **Biological and Clinical Implications of Exon 8 P53 (R282W) Gene Mutation in Relation to Development and Progression of Chronic Myeloid Leukaemia Patients in Indian Population.** J Cell Sci Ther. 2013; 4(1):1-6. (Impact Factor:3.09).
24. Jamsheed Javid, **Rashid Mir**, Alpana saxena. **Involvement of CASP3 promoter polymorphism (-1337 C>G) in the development and progression of Non-small cell lung cancer.** Tumour Biol. Jan 2016. TUBI-D-15-03211R1 (Accepted) (Impact Factor: 3.61)
25. Jamsheed Javid, **Rashid Mir**, P.K Julka, P.C Ray, Alpana saxena. **Extra cellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of Non Small Cell Lung Cancer patients.** Tumour Biol. 2015. 2015 Jun; 36(6):4253-60. (Impact Factor: 3.61)
26. Jamsheed Javid, **Rashid Mir**, P.K Julka, P.C Ray, Alpana saxena. **Association of p53 and mdm2 in the development and progression of Non small cell lung cancer.** Tumour Biol. 2015 ;36(7):5425-32. (Impact Factor: 3.61) *PUBMED*.
27. Jamsheed Javid, **Rashid Mir**, P.K Julka, P.C Ray, Alpana saxena. **Role of survivin re-expression in the development and progression of Non Small Cell Lung Cancer.** Tumour Biol. 2015 ;36(7):5543-50. (Impact Factor: 3.61) *PUBMED*.
28. Jamsheed Javid, **Rashid Mir**, Masroor M, Imtiyaz Ahamad, Prashant Y, Alpana Saxena, et al. **CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome of non-small cell lung cancer patients.** Clin Transl Oncol. 2015; 17(4):289-95. (Impact Factor: 2.1) *PUBMED*.
29. Jamsheed Javid, **Rashid Mir**, P.K Julka, P.C Ray, Alpana saxena. **BAX G(-248)A gene polymorphism and its association with risk of Non-small cell lung cancer- a case control study.** Open J Apoptosis, 2015; 4(2):47-58. DOI: 10.4236/ojapo.2015.42005 (Impact Factor: 0.64) *PUBMED*.
30. Mirza Masroor, Jamsheed Javid, **Rashid Mir**, Prasant Y, Imtiyaz A, Alpana Saxena et al. **Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients** Tumour Biol. 2015; DOI:10.1007/s13277-015-3859-3 (Impact Factor: 3.61)

31. Mirza Masroor, Jain Amit, Jamsheed Javid, **Rashid Mir**, Y Prasant , Alpana Saxena, et al. **Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study.** APJCP. 2015; 16(17):7529-34. (Impact Factor: 2.51). *PUBMED*
32. Mirza Masroor, Amit Jain, Jamsheed Javid, **Rashid Mir**, Y Prasant , Alpana Saxena, et al. **Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients** APJCP.2015; 16(17):7653-8. (Impact Factor: 2.51) *PUBMED*.
33. Masoor M, **Rashid Mir**, Jamsheed Javid, Prasant Y, Imtiyaz A , Alpana saxena et al. **Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases.** APJCP 10/2015;16(15):6445-9. (Impact Factor: 2.51) *PUBMED*.
34. P. Yadav, M Masroor, K. Tanwer, **Rashid Mir**, Jamsheed Javid, A.Saxena et al. **Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.** Clin Transl Oncol. 2015, DOI: 10.1007/s12094-015-1425-5 (Impact Factor: 2.1) *PUBMED*.
35. **Rashid Mir**, Imtiyaz A, Jamsheed Javid, Shazia F, Alpana S et al .**Hypermethylation is Associated With Disease Progression and Resistance to Imatinib in Indian Chronic Myelogenous Leukemia Patients.** Clin Lymphoma Myeloma Leuk DOI: 10.1016/j.clml. 2014.06.073. (Impact Factor: 2.02) *PUBMED*.
36. Sameer G, Imtiyaz A, **Rashid Mir**, Jamsheed Javid, Shazia F, Alpana S et al. Biological and Clinical Implications of Exon 8 P53 (R282W) Gene Mutation in Relation to Development and Progression of CML Patients in India Population. Clin Lymphoma Myeloma Leuk DOI: 10.1016/j.clml.2014.06.074 (Impact Factor: 2.02) *PUBMED*.
37. Shazia Farooq, M. A. Siddiqui, P. C. Ray, M. Q. Sheikh, Sheikh Shah Nawaz, M. Ashraf Bhat, M. R. Mir, M. Z. Abdin, Imtiyaz Ahmad, Jamsheed Javid, Prasant Yadav, M. Masroor, Mariyam Zuberi, Alpana Saxena and **Rashid Mir**. **Genetic diversity analysis in the Hypericum perforatum populations in the Kashmir valley by using inter-simple sequence repeats (ISSR) markers.** African J Biotechnology. 2014; 13(1):18-31.
38. Imtiyaz Ahamad, **Rashid Mir**, Mariyam Zuberi, Jamsheed Javid, Shazia Farooq, Prasant Yadav, et al. **Inactivation of RIZ1 gene by promoter hypermethylation is associated with disease progression and resistance to Imatinib in Indian Chronic myelogenous leukemia patients, first study from India.** J Cancer Sci Ther. 2013; 5(2):045-051.
39. Dholariya S, Zubari M, Ray PC, Gandhi G, Khurana N, Yadav P, Mohapatra S, Jamsheed Javid, Ahamad I ,Saxena A, **Rashid Mir**. TP53 Gene Polymorphism in Epithelial Ovarian Carcinoma Patients from North Indian Population and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility. J Genet Syndr Gene Ther. 2013; 4(5):1-6.
40. Jamsheed Javid, **Rashid Mir**, Masroor M, Imtiyaz Ahamad, Shazia Farooq, Alpana Saxena et al. TP53 is a Mutational Target in Non Small Cell Lung Cancer Patients and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility. J Carcinogenesis & Mutagenesis. 2013; 4(1):1-7
41. Jamsheed Javid, **Rashid M**, Masroor M, Shazia F, Imtiyaz A, Alpana S, et al. Biological and Clinical Implications of Functional Promoter Polymorphism of CASPASE 9 Gene in NSCLC Patients. J Mol Biomarkers Diagn. 2013; S (8):1-7.
42. Jamsheed Javid, Masroor M, **Rashid Mir**, Imtiyaz Ahamad, Shazia Farooq, Alpana Saxena et al. Clinical and Prognostic Significance of R282W p53 gene mutation in North India Patients with Non Small Cell Lung Carcinoma. Translational Medicine. 2012; 2(2):1-5. (Impact Factor: 0.5).
43. Jamsheed Javid , **Rashid Mir**, Imtiyaz Ahamad, Shazia Farooq, Prasant Yadav, Alpana Saxena et al. Clinical and Prognostic Significance of Promoter Polymorphism (-31GC) of Anti Apoptotic Gene Survivin (BIRC5) in North Indian Patients with Non-Small Cell Lung Cancer. J Cancer Sci Ther.2012; 4(9):276-280.
44. Jamsheed Javid, **Rashid Mir**, Masroor, Shazia F, Alpana S, et al. Impact of MDM2 SNP309T>G Polymorphism: Increased risk of developing Non Small Cell Lung Cancer and Poor Prognosis in Indian Patients. J Cancer Sci Ther.2012; 4(10):341-346
45. Amle D, **Rashid Mir**, Khaneja A, Agarwal S, Ahlawat R, Ray PC, Saxena A.**Association of 18bp insertion/deletion polymorphism, at -2549 position of VEGF gene, with diabetic nephropathy in type 2 diabetes mellitus patients of North Indian population.**J Diabetes Metab Disord. 2015 Mar 27;14:19.

46. Dholariya S, **Rashid Mir**, Zuberi M, Yadav P, Gandhi G, Khurana N, Saxena A, Ray PC. **Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.** Clin Transl Oncol. 2015 Jul 25 . (Impact Factor: 1.09).

Under publication -05

UNDER REVIEW -05

REFERENCES

Dr. Alpana Saxena

Director Professor & Head, Department of Biochemistry,
Maulana Azad Medical College and associated Hospitals, New Delhi, India.
Email: alpanasaxena@hotmail.com

Dr. P C Ray

Director Professor & Head, Department of Biochemistry,
Maulana Azad Medical College and associated Hospitals, New Delhi, India.
Email: drpcraymamc@hotmail.com

I certify that all the stated information's are true and valid

Dr. Rashid Mir

SIGNATURE OVER NAME